Athenex, texas children's cancer center, and the center for cell and gene therapy at baylor college of medicine present new clinical data on gd2 car-nkt cells in neuroblastoma at asgct annual meeting

Buffalo, n.y., may 17, 2021 (globe newswire) -- athenex, inc. (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its orascovery platform, today announced that investigators from texas children's cancer center and the center for cell and gene therapy at baylor college of medicine presented new clinical data from the ongoing ginakit2 phase 1 study of athenex's cell therapy candidate kur-501 targeting gd2 in neuroblastoma at the american society of gene & cell therapy (asgct) 24 th annual meeting on friday, may 14, at 11 am et.
ATNX Ratings Summary
ATNX Quant Ranking